2405:201:D002:39CC:CCB0:C992:6EB7:61C at 07:42, 5 July 2021

2021-07-05T07:42:37Z

New page

{{Short description|Indian multinational biopharmaceutical company}}
{{multiple issues|
{{advert|date=April 2012}}
{{COI|date=May 2016}}
{{cleanup reorganize|date=May 2016}}
{{more citations needed|date=May 2016}}
}}
{{Use Indian English|date=December 2020}}
{{Use dmy dates|date=September 2020}}

{{Infobox company
| name = Biocon Limited
| logo = Biocon Logo.svg
| type = [[Public company|Public]]
| traded_as = {{BSE|532523}} {{NSE|BIOCON}}
| founder = [[Kiran Mazumdar-Shaw]]
| key_people = [[Kiran Mazumdar-Shaw]] (Chairperson & MD) 
Siddharth mittal (CEO & Joint Managing Director) 
| ISIN = INE376G01013
| industry = [[Biopharmaceutical]]
| products = [[Biologics]] Small Molecules Branded Formulations Research Services
| services =
| revenue = {{Increase}} {{INRConvert|6528.60|c}} <ref name=pls>{{Cite web|title=Biocon Consolidated Profit & Loss account, Biocon Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/biocon/consolidated-profit-lossVI/bl03|access-date=31 July 2020|website=www.moneycontrol.com|language=en}}</ref>
| revenue_year = 2020
| operating_income = {{Increase}} {{INRConvert|1214.90|c}} <ref name=pls/>
| income_year = 2020
| net_income = {{Decrease}} {{INRConvert|748.20|c}} <ref name=pls/>
| net_income_year = 2020
| assets = {{Increase}} {{INRConvert|14443.80|c}} <ref name=bls>{{Cite web|title=Biocon Consolidated Balance Sheet, Biocon Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/biocon/consolidated-balance-sheetVI/bl03|access-date=31 July 2020|website=www.moneycontrol.com|language=en}}</ref>
| assets_year = 2020
| equity = {{Increase}} {{INRConvert|6705.80|c}} <ref name=bls/>
| equity_year = 2020
| num_employees = 9,234 (Mar 2017)<ref name="biocon2017">{{cite web|url=http://www.biocon.com/docs/Biocon_Annual_Report_2017.pdf|title=Biocon Annual Report 2017|publisher=Biocon}}</ref>
| subsid = Syngene 
| intl =
| foundation = {{Start date and age|1978|p=y}}
| slogan =
| location_city = [[Bangalore, Karnataka]]
| location_country = [[India]]
| homepage = {{URL|www.biocon.com}}
}}

'''Biocon Limited''' is an Indian [[biopharmaceutical]] company based in [[Bangalore]], [[India]] founded by Kiran Mazumdar-Shaw.<ref name="ref1" /> The company manufactures [[Generic drug|generic]] active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe,{{citation needed|date=September 2020}} including the developed markets of the United States and Europe.<ref name="ref1" /> It also manufactures novel biologics, as well as, [[biosimilar insulins]] and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.{{citation needed|date=March 2021}} In contract research services, '''Syngene International Limited''' (Syngene), a publicly listed subsidiary of Biocon.

Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb(Itolizumab) and KRABEVA (Bevacizumab).<ref name="ref1" />

Biocon and Syngene together employ about 9200 personnel.<ref name="ref1" />

==History==
Biocon was founded in 1978 with Rs. 10,000 as the initial capital.<ref>{{Cite web|last=Egan|first=Mary Ellen|title=Big Shot in Bangalore|url=https://www.forbes.com/forbes/2004/1018/088.html|access-date=2021-03-07|website=Forbes|language=en}}
</ref>
* 1979 - Becomes the first Indian company to manufacture and export enzymes to USA and Europe.<ref>{{Cite web|url=http://www.indianmirror.com/indian-industries/top-industries/biocon.html|title=Biocon, India's largest biotech company.|last=nimmi|website=www.indianmirror.com|language=en-US|access-date=8 February 2018}}</ref>
* 1989 - [[Unilever]] acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.<ref name="ref8" />
* 1994 - Establishes [http://www.syngeneintl.com/ Syngene International Pvt. Ltd]. as a Custom Research Company (CRC).<ref name="ref8" />
* 1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.<ref>{{Cite book|url=https://books.google.com/books?id=a9WGAwAAQBAJ&q=1998%E2%80%94Unilever+agrees+to+sell+its+shareholding+in+Biocon+to+the+Indian+promoters.+Biocon+becomes+an+independent+entity&pg=PA214|title=Winning Strategies for Business|last=Baisya|first=Rajat K.|date=9 September 2010|publisher=SAGE Publications India|isbn=9788132106081|language=en}}</ref>
* 2001 - Becomes the first Indian company to be approved by [[Food and Drug Administration|USFDA]] for the manufacture of [[lovastatin]]; PlaFractor is granted a US 2001 and worldwide patent.<ref>{{Cite book|url=https://books.google.com/books?id=az8D9OOvfF0C&q=biocon+Becomes+the+first+Indian+company+to+be+approved+by+USFDA+for+the+manufacture+of+lovastatin&pg=PA654|title=Strategic Management 10E|last=Pearce|date=2009|publisher=McGraw-Hill Education (India) Pvt Limited|isbn=9780070264380|language=en}}</ref>
* 2003 - Biocon becomes the first company worldwide to develop human insulin on a [[Pichia pastoris|Pichia]] expression system.<ref>{{Cite web|url=https://www.brandindiapharma.in/pharmaceutical-companies-india/biocon-limited|title=Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address|website=www.brandindiapharma.in|access-date=8 February 2018}}</ref>
* 2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and [[A. P. J. Abdul Kalam|Dr. APJ Abdul Kalam]] inaugurates India's Largest Biotech-Hub "Biocon Park".<ref>{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=95300|title=Dr. APJ Abdul Kalam Dedicates India\'s First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India\'s Largest Biotech-Hub "Biocon Park" {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}</ref>
* * 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.<ref>{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=149061&sectionID=&isEPVantage=no|title=Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}</ref>
* 2009 - Syngene-[[Bristol-Myers Squibb|Bristol Myers Squibb]] research facility is established in Bengaluru.<ref>{{Cite book|url=https://books.google.com/books?id=aoHRAwAAQBAJ&q=syngene+bms+partnership+2009&pg=PA451|title=India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing|last=Burns|first=Lawton R.|date=13 January 2014|publisher=Cambridge University Press|isbn=9781107044371|language=en}}</ref>
* 2009 - [[Mylan]] announces strategic collaboration with Biocon to Enter the Global Generic Biologics Market.<ref>{{Cite news|url=http://newsroom.mylan.com/press-releases?item=122588|title=Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market|work=MediaRoom|access-date=8 February 2018}}</ref>
* 2010 - Biocon expands to Malaysia, biopharmaceutical manufacturing and R&D facility established in [[Iskandar]] Malaysia, [[Johor]].<ref>{{Cite news|url=https://www.asianscientist.com/2011/09/pharma/biocon-limited-rnd-facility-bio-xcell-malaysia/|title=Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia|date=11 September 2011|work=Asian Scientist Magazine {{!}} Science, technology and medical news updates from Asia|access-date=8 February 2018|language=en-US}}</ref>
* 2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device.<ref>{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=259989|title=Biocon Launches INSUPen®, a Convenient and Affordable Reusable Insulin Delivery Device {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}</ref>
* 2012 - [[Abbott Laboratories|Abbott]] announces collaboration with Syngene to Open First Nutrition R&D Center in India.<ref>{{Cite web|url=https://www.prnewswire.com/news-releases/abbott-announces-collaboration-with-syngene-to-open-first-nutrition-rd-center-in-india-149948055.html|title=Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India|last=Abbott|website=prnewswire.com|language=en|access-date=8 February 2018}}</ref>
* 2013 - Biocon launches biologic drug ALZUMAb to treat [[psoriasis]].<ref>{{Cite news|url=http://www.thehindubusinessline.com/companies/Biocon-unveils-biologic-drug-to-treat-skin-disorder/article20647520.ece|title=Biocon unveils biologic drug to treat skin disorder|work=@businessline|access-date=8 February 2018|language=en}}</ref>
* 2014 - Biocon launches world's first biosimilar drug CANMAb to treat [[breast cancer]].<ref>{{cite web|url=http://timesofindia.indiatimes.com/business/india-business/Kiran-Mazumdar-Shaws-Biocon-develops-new-breast-cancer-drug/articleshow/29016754.cms |title=Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug |publisher=indiatimes.com |date=18 January 2014 |access-date=19 January 2014}}</ref>
* 2015 - Biocon launches [[hepatitis-C]] drug in India under brand name CIMIVIR-L.<ref>{{Cite news|url=http://www.livemint.com/Companies/78WwKeykyzx3G5X4AhcQKJ/Biocon-launches-hepatitisC-drug-in-India.html|title=Biocon launches hepatitis-C drug in India|last=Pilla|first=Viswanath|date=24 December 2015|work=livemint.com/|access-date=8 February 2018}}</ref>
* 2016 - Becomes the first Indian company to launch a [[biosimilar]] [[Insulin glargine|Insulin Glargine]] pen in Japan.<ref>{{Cite news|url=http://www.livemint.com/Companies/T3byt5dkq71gZoWez8fhRL/Biocons-partner-FUJIFILM-launches-insulin-glargine-in-Japan.html|title=Biocon's partner FUJIFILM launches insulin glargine in Japan|last=Pilla|first=Viswanath|date=15 July 2016|work=livemint.com/|access-date=20 December 2017}}</ref>
* 2016 - Syngene sets up [[Amgen]] R&D center in Bangalore.<ref>{{Cite web|url=https://www.fiercebiotech.com/cro/indian-cro-syngene-sets-up-amgen-r-d-center-bangalore|title=Indian CRO Syngene sets up Amgen R&D center in Bangalore {{!}} FierceBiotech|website=www.fiercebiotech.com|language=en|access-date=8 February 2018}}</ref>
* 2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.<ref>{{Cite web|url=https://www.biosimilardevelopment.com/doc/biocon-wins-myr-million-contract-for-insulin-from-moh-malaysia-0001|title=Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia|website=www.biosimilardevelopment.com|language=en|access-date=20 December 2017}}</ref>
* 2017 - USFDA approves [[Mylan]]-Biocon's biosimilar for cancer drug [[Trastuzumab|Herceptin]].<ref>{{Cite news|url=http://www.livemint.com/Industry/AdFKCQcZvRRXnToosfdMbO/US-FDA-approves-MylanBiocons-biosimilar-for-cancer-drug-He.html|title=US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin|last=Trivedi|first=Isha|date=2 December 2017|work=livemint.com/|access-date=8 February 2018}}</ref>
* 2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.<ref>{{cite news |title=Biocon, Mylan get European Commission approval to market biosimilar insulin glargine|url=https://business.medicaldialogues.in/biocon-mylan-get-european-commission-approval-market-biosimilar-insulin-glargine/ |publisher= Business Medical Dialogues|date=30 March 2018 }}</ref>

==Corporate governance==
[[File:STR 6036.jpg|thumb|Kiran Mazumdar-Shaw is an Indian entrepreneur. She founded Biocon in 1978.]]
Biocon's CMD [[Kiran Mazumdar-Shaw|Kiran Mazumdar–Shaw]] joined Biocon in 1978.<ref name="ref12"/><ref name="ref13"/><ref name="ref14"/>

Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon and she has been called India's 'biotech queen' by [[The Economist]]<ref name="ref15"/> and India's 'mother of invention' by [[The New York Times]].<ref name="ref16"/> She was recently named{{when|date=March 2021}} among [[Time (magazine)|TIME]] magazine's 100 most influential people in the world based not only on her contribution to the biotech industry but also because she gives back to the community.<ref name="ref17"/> Ms Shaw features on the [[Forbes]] list of ‘The World’s 100 Most Powerful Women’<ref name="ref18"/> and in [[Financial Times]]’ ‘Top 50 Women in Business’ list<ref name="ref19"/>

Shaw is the recipient of several awards including the [[Nikkei Asia Prize]], 2009 for Regional Growth,<ref name="ref21"/> Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, [[The Economic Times]] ‘Businesswoman of the Year’, the ‘[[Veuve Clicquot]] Initiative For Economic Development For Asia, [[Ernst & Young]]’s Entrepreneur of the Year Award for Life Sciences & Healthcare, ‘Technology Pioneer’ recognition by World Economic Forum and The Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards—[[Padma Shri]] (1989) and [[Padma Bhushan]] (2005) for her pioneering efforts in Industrial Biotechnology.<ref name="ref12"/>

Biocon announced that Dr. Christiane Hamacher has been appointed as the CEO of Biocon Biologic India Limited, with her term having started in March 2019.<ref>{{cite news|url=https://business.medicaldialogues.in/biocon-appoints-christiane-hamacher-as-ceo-of-biocon-biologics-india/|title=Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India|date=2 March 2019|work=Medical Dialogues}}</ref>

On 3 December 2019, Siddharth Mittal took over from Dr. Arun Chandavarkar who retired as [[Chief Executive Officer|CEO]] & Joint Managing Director of Biocon.<ref>{{cite news|date=3 December 2019|title=Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar|publisher=Medical Dialogues|url=https://business.medicaldialogues.in/biocon-names-siddharth-mittal-as-new-ceo-joint-md-bids-farewell-to-arun-chandavarkar/}}</ref>

==Subsidiaries==

===Syngene International Ltd===

Established in 1993, Syngene International Limited is Biocon's custom research organisation offering pharmaceutical and biotechnology majors customized solutions in synthetic chemistry and molecular biology for early-stage drug discovery and development.{{citation needed|date=March 2021|reason=date, need to cite}}

===Clinigene===

Clinigene International Limited is a subsidiary on Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.<ref name="ref12"/>

===BBPL===

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.<ref name="ref12"/>

===Biocon-AxiCorp===

In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.{{citation needed|date=March 2021|reason=statistic/date, need to cite}}

===NeoBiocon===

Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in [[Abu Dhabi]].{{citation needed|date=March 2021|reason=date, need to cite}}

===Biofusion Therapeutics Limited===

Incorporated in March of 2021, 100% owned by Biocon.

==Strategic Partnerships==
===Biocon and Amylin===

In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.<ref name="ref12"/>

===Biocon and IATRICa===

In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell mediated immunity is enhanced and maintained against a tumor which otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.<ref name="ref12"/>

===Biocon and Mylan===

In 2009, Biocon signed a collaboration agreement with Mylan to develop and commercialize generic biologics. Mylan and Biocon will share development, capital and other costs to bring products to market. Mylan will have exclusive commercialisation rights in USA, Canada, Japan, Australia, New Zealand, EU and European Free Trade Association countries through a profit sharing arrangement with Biocon.<ref name="ref12"/>

===Biocon and Optimer===

Biocon and Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as Clostridium Difficile Infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.,<ref name="ref1"/><ref name="ref12"/>

===Biocon and Vaccinex===

Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients suffering from rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.,<ref name="ref1"/><ref name="ref12"/>

===Biocon and Abraxis===

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement which helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.<ref name="ref12"/>

=== Biocon and Sandoz ===
In January 2018, [[Sandoz]] (a [[Novartis]] division) announced a global partnership with Biocon to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. .<ref>{{Cite web|url=https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars|title=Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars {{!}} Novartis|website=Novartis|language=en|access-date=8 February 2018}}</ref>

==Biocon technology==

Biocon's manufacturing facilities are located at two sites in [[Bangalore]].<ref name="ref12"/>

==Research & development capabilities ==
Biocon's [[R&D]] focuses on the entire drug development pathway – from process development to non-clinical and clinical research.<ref name="ref12"/>

==Products==

Biocon offers 36 brands of products across the four therapeutic divisions of [[diabetes|diabetology]], [[nephrology]], [[oncology]], and [[cardiology]].<ref name="ref1"/>

==References==
{{Reflist|refs=



<ref name="ref1">{{Cite web |url=http://www.biocon.com/docs/AR10-BIOCON.pdf |title=Biocon Annual Report, 2010 |access-date=20 September 2010 |archive-url=https://web.archive.org/web/20101026031837/http://biocon.com/docs/AR10-BIOCON.pdf |archive-date=26 October 2010 |url-status=dead }}</ref>




<ref name="ref8">Kiran Mazumdar-Shaw, CMD, Biocon Ltd, [http://www.outlookmoney.com/article.aspx?88528 ‘Biotech Is Not for Punters’], Outlook Money, 15 July 2004</ref>


<ref name="ref12">Biocon Website ({{cite web |url=http://biocon.com/ |title=Archived copy |access-date=3 August 2014 |url-status=dead |archive-url=https://web.archive.org/web/20140807042606/http://www.biocon.com/ |archive-date=7 August 2014 }})</ref>
<ref name="ref13">Nature Reviews Drug Discovery, July 2010</ref>
<ref name="ref14">Biospectrum India Friday, 11 July 2008</ref>
<ref name="ref15">Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001</ref>
<ref name="ref16">[https://www.nytimes.com/2003/08/16/world/the-saturday-profile-how-india-s-mother-of-invention-built-an-industry.html "How India's Mother of Invention Built an Industry"], 16 August 2003</ref>
<ref name="ref17">Time, 29 April 2010</ref>
<ref name="ref18">The World's 100 Most Powerful Women, Forbes, 19 August 2009</ref>
<ref name="ref19">FT top 50 women in world business, Financial Times, 25 September 2009</ref>

<ref name="ref21">The Hindu, 12 May 2009</ref>



}}
{{Commons category|Biocon}}

{{Nifty 200 companies}}
{{Bangalore topics}}
{{Authority control}}

[[Category:Biotechnology companies of India]]
[[Category:Pharmaceutical companies established in 1978]]
[[Category:Pharmaceutical companies of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Manufacturing companies based in Bangalore]]
[[Category:Biotechnology companies established in 1978]]
[[Category:Indian companies established in 1978]]
[[Category:Indian brands]]
[[Category:1978 establishments in Karnataka]]

Biocon - Revision history

2405:201:D002:39CC:CCB0:C992:6EB7:61C at 07:42, 5 July 2021